Recurring Extracorporeal Circuit Clotting During Continuous Renal Replacement Therapy Resolved after Single-Session Therapeutic Plasma Exchange

被引:2
作者
Fueloep, Tibor [1 ,2 ]
Cosmin, Adrian [2 ]
Juncos, Luis A. [2 ,3 ]
机构
[1] Univ Mississippi, Med Ctr, Dept Internal Med, Div Nephrol, Jackson, MS 39216 USA
[2] Univ Mississippi Hlth Care, Dept Internal Med, Div Nephrol, Jackson, MS USA
[3] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA
关键词
anticoagulation; clotting; continuous renal replacement therapy; fibrinogen; therapeutic plasma exchange; FIBRINOGEN APHERESIS; ABNORMALITIES; FILTRATION; CLEARANCE;
D O I
10.1002/jca.20291
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report a case of a 17-year-old white male with multiple fractures and multiorgan failure who developed oliguric acute renal failure requiring continuous renal replacement therapy. Repeated clotting of the extracorporeal circuit (ECC) prevented delivery of a minimally acceptable dose of renal replacement therapy despite adequate anticoagulation and dialysis catheter exchanges. Evaluation for a primary hypercoagulable state was negative, but his fibrinogen was elevated (1,320 mg/dL, normal range: 150-400 mg/dL), which is likely induced by his severe inflammatory state. A single session of therapeutic plasma exchange (TPE) with albumin and normal saline replacement was performed with subsequent drop in fibrinogen to 615 mg/dL. No further episodes of premature ECC clotting occurred, suggesting plasma factor(s) removed may have contributed to the clinical hypercoagutable state. TPE may play an adjunctive role in select cases of recurrent ECC clotting refractory to current anticoagulation techniques. J. Clin. Apheresis 26:214-215, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:214 / 215
页数:2
相关论文
共 10 条
[1]  
CHIRNSIDE A, 1981, BRIT J HAEMATOL, V48, P627
[2]   A VISCOMETRIC METHOD OF MEASURING PLASMA-FIBRINOGEN CONCENTRATIONS [J].
ERNST, E ;
RESCH, KL ;
SARADETH, T ;
MAIER, A ;
MATRAI, A .
JOURNAL OF CLINICAL PATHOLOGY, 1992, 45 (06) :534-535
[3]   Selective fibrinogen apheresis for improvement in microvascular hemodynamics [J].
Kaplan, Andre A. .
BLOOD PURIFICATION, 2007, 25 (5-6) :402-403
[4]   VISCOSIMETRIC EFFECT OF FIBRINOGEN [J].
LANE, DW ;
LANSON, S .
JOURNAL OF CLINICAL PATHOLOGY, 1994, 47 (11) :1004-1005
[5]   Clearance of fibrinogen and von Willebrand factor in serial double-filtration plasmapheresis [J].
Lin, SM ;
Yeh, JH ;
Lee, CC ;
Chiu, HC .
JOURNAL OF CLINICAL APHERESIS, 2003, 18 (02) :67-70
[6]   Fibrinogen apheresis in the treatment of peripheral arterial disease [J].
Ramunni, A. ;
Brescia, P. ;
Quaranta, D. ;
Plantamura, M. ;
Ria, R. ;
Coratelli, P. .
BLOOD PURIFICATION, 2007, 25 (5-6) :404-410
[7]   A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration [J].
Reeves, JH ;
Cumming, AR ;
Gallagher, L ;
O'Brien, JL ;
Santamaria, JD .
CRITICAL CARE MEDICINE, 1999, 27 (10) :2224-2228
[8]   A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance [J].
Tolwani, Ashita J. ;
Prendergast, Mary B. ;
Speer, Rajesh R. ;
Stofan, Brenda S. ;
Wille, Keith M. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (01) :79-87
[9]  
Wood L, 1986, J Clin Apher, V3, P124, DOI 10.1002/jca.2920030209
[10]   HEMOSTATIC ABNORMALITIES IN PATIENTS WITH PULMONARY-EMBOLISM COMPARED WITH THAT IN DEEP-VEIN THROMBOSIS [J].
YAMADA, N ;
WADA, H ;
NAKASE, T ;
MINAMIKAWA, K ;
NAGAYA, S ;
NAKAMURA, M ;
HIRAOKA, N ;
FUZIOKA, H ;
HAYASHI, T ;
SUZUKI, K ;
NAKANO, T ;
SHIKU, H .
BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (07) :627-633